Efficacy and Safety of rhEGF in Diabetic Foot Ulcer Patients With Uncontrolled Diabetic Mellitus

The Clinical Trial for Evaluation of Efficacy and Safety of rhEGF(Recombinant Human Epidermal Growth Factor) in Diabetic Foot Ulcer Patients With Uncontrolled Diabetes Mellitus.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01629199

Enrollment

176

Registered

2012-06-27

Start date

2010-10-31

Completion date

2012-09-30

Last updated

2014-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot Ulcer Patients With Uncontrolled Diabetes Mellitus

Brief summary

The purpose of this clinical trial is to evaluate the safety and efficacy of rhEGF (recombinant human Epidermal Growth Factor) in diabetic foot ulcer patients with uncontrolled diabetes mellitus.

Interventions

DRUGrhEGF(recombinant human Epidermal Growth Factor)

DRUGplacebo of rhEGF(recombinant human Epidermal Growth Factor)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Design outcomes

Primary

Measure	Time frame
At 12 weeks, wound closure rate of diabetic foot ulcers	12 weeks from the start day of treatment (But, the study can be finished before 12 weeks)

Secondary

Measure	Time frame
Time to reach complete wound closure	12weeks
average size reduction of diabetic ulcer	12 week

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026